TORCH: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed/refractory Diffuse Large B cell Lymphoma (DLBCL).

Trial Overview and Summary

We want to see if a medicine called AZD2014 is effective and safe to use when treating 30 patients with relapsed or refractory Diffuse Large B Cell Lymphoma. In six patients we will also add the medicine Rituximab to AZD2014 to see if this can be done without increasing the toxicity of AZD2014. 

AZD2014 will be given as tablets to be swallowed twice a day on days 1 and 2 of every week.  Rituximab will be infused into the blood vessels on day 1 of every 28 days (once every 4 weeks) for a maximum of 6 cycles.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator: Dr Graham Collins 
Sponsor: The University of Birmingham
Funders: Bloodwise (TAP)
Disease Site: Diffuse Large B cell Lymphoma
Trial Type: Clinical Trial of an Investigational Medicinal Product
Status: Follow-up
UKCRN Study ID: (if applicable) 19208
Open to new sites? No
Recruitment start date: 19-Oct-2015
Recruitment end date 25-Apr-2017
CRCTU Trial Management Team: Haematology
Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More Information

Please Note:

CancerHelp (Cancer Research UK) - TORCH trial